bioRxivCell BiologyPreprint
Subcellular mapping of the protein landscape of SARS-CoV-2 infected cells for target-centric drug repurposing
J. M. Kaimal, M. Tampere, T. H. Le, U. Axelsson, H. Xu, H. Axelsson, A. Backstrom, F. Marabita, E. Moussaud-Lamodiere, D. Njenda, C. O. Sepulveda, W. Ouyang, B. Seashore-Ludlow, C. Vernersson, A. Mirazimi, E. Lundberg, P. Ostling, C. Stadler
Abstract
The COVID-19 pandemic has resulted in millions of deaths and affected socioeconomic structure worldwide and the search for new antivirals and treatments are still ongoing. In the search for new drug target and to increase our understanding of the disease, we used large scale immunofluorescence to explore the host cell response to SARS-CoV-2 infection. Among the 602 host proteins studied in this host response screen, changes in abundance and subcellular localization were observed for 97 proteins, with 45 proteins showing increased abundance and 10 reduced abundances. 20 proteins displayed changed localization upon infection and an additional 22 proteins displayed altered abundance and localization, together contributing to diverse reshuffling of the host cell protein landscape. We then selected existing and approved small-molecule drugs (n =123) against our identified host response proteins and identified 3 compounds - elesclomol, crizotinib and rimcazole, that significantly reduced antiviral activity. Our study introduces a novel, targeted and systematic approach based on host protein profiling, to identify new targets for drug repurposing. The dataset of [~]75,000 immunofluorescence images from this study are published as a resource available for further studies.
- organism: human
- assay: imaging
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Morphological cell profiling for drug repurposing against SARS-CoV-2 infection
Elin Asp, Jonne Rietdijk, … Päivi Östling·bioRxiv·Aug 28, 2025
- Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo.
J. Patten, P. T. Keiser, … R. A. Davey·bioRxiv·Apr 20, 2021
- A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing
David Ezra Gordon, Gwendolyn Μ. Jang, … Natalia Jura·NaturePeer-reviewed·Apr 30, 2020
- Elucidating host cell response pathways and repurposing therapeutics for SARS-CoV-2 and other coronaviruses using gene expression profiles of chemical and genetic perturbations
Zhewei Shen, Anna Halberg, … Pek Yee Lum·bioRxiv·Apr 18, 2022
- A BioID-derived proximity interactome for SARS-CoV-2 proteins
Danielle G. May, Laura Martin‐Sancho, … Kyle J. Roux·VirusesPeer-reviewed·Mar 15, 2022
- Characterisation of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets with therapeutic potential
B. Meyer, J. Chiaravalli, … E. Emmott·bioRxiv·Sep 16, 2020